{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106149","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.042294+00:00","generated_at":"2026-06-10T05:38:14.941565+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics updates investor deck highlighting pipeline, Allo-Evasion 3.0, and cash runway into 2026","bullets":["Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.","ELiPSE-1 trial for CNTY-101 (iNK CD19) ongoing; initial data expected by end of 2023, PoC in 2024.","Pipeline includes CNTY-102 (iT CD19/CD22 dual-target) and CNTY-107 (iT Nectin-4); BMS collaboration for CNTY-104 (AML) and CNTY-106 (myeloma).","Allo-Evasion 3.0 incorporates 4 edits (β2M KO, CIITA KO, HLA-E KI, HLA-G KI) to protect against NK cell killing.","CNTY-101 designed with Allo-Evasion to enable repeat dosing without additional lymphodepletion; first CD19 agent with this approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106149","json":"https://secwatch.observer/filing/0001104659-23-106149.json","markdown":"https://secwatch.observer/filing/0001104659-23-106149.md","text":"https://secwatch.observer/filing/0001104659-23-106149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/0001104659-23-106149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923106149/tm2327303d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:38:14.941565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}